Shamburg News · 8-K filed Nov 10, 2026, 4:06 PM EST

Inovio Reports Third Quarter 2026 Results; Net Loss of $49.2 Million, or $0.50 Per Share

INO · INOVIO PHARMACEUTICALS, INC.

  • Earnings
  • Materiality: high

Inovio Pharmaceuticals reported third quarter 2026 results, including a net loss of $49.2 million, or $0.50 per basic and diluted share, compared with a net loss of $45.5 million, or $0.87 per share, a year earlier. Revenue from collaborative arrangements was $298,901 for the quarter, and research and development expenses decreased to $10.6 million while SG&A rose to $9.2 million. The company also reported that the FDA granted accelerated approval for VOCERYQ on October 30, 2026 and that net proceeds of approximately $80.5 million from a November 2026 public offering support the launch.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001055726-26-000030.

Written from the filing by Shamburg Markets. Figures are as reported by the company.